ES2592963T3 - Soporte sólido y método para aumentar la recuperación de material biológico del mismo - Google Patents
Soporte sólido y método para aumentar la recuperación de material biológico del mismo Download PDFInfo
- Publication number
- ES2592963T3 ES2592963T3 ES12705857.6T ES12705857T ES2592963T3 ES 2592963 T3 ES2592963 T3 ES 2592963T3 ES 12705857 T ES12705857 T ES 12705857T ES 2592963 T3 ES2592963 T3 ES 2592963T3
- Authority
- ES
- Spain
- Prior art keywords
- paper
- biological material
- solid support
- recovery
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007787 solid Substances 0.000 title claims abstract description 31
- 239000012620 biological material Substances 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000011084 recovery Methods 0.000 title claims description 26
- 239000000126 substance Substances 0.000 claims abstract description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 13
- 102000009027 Albumins Human genes 0.000 claims abstract description 11
- 108010088751 Albumins Proteins 0.000 claims abstract description 11
- 239000005018 casein Substances 0.000 claims abstract description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000021240 caseins Nutrition 0.000 claims abstract description 10
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 229960000074 biopharmaceutical Drugs 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- -1 polypropylene Polymers 0.000 claims description 3
- 229920001410 Microfiber Polymers 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000003658 microfiber Substances 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 2
- 239000004677 Nylon Substances 0.000 claims 1
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 229920001778 nylon Polymers 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 150000008053 sultones Chemical class 0.000 claims 1
- 239000000123 paper Substances 0.000 description 54
- 108010002350 Interleukin-2 Proteins 0.000 description 28
- 102000000588 Interleukin-2 Human genes 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 12
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000012216 screening Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011027 product recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103258.8A GB201103258D0 (en) | 2011-02-25 | 2011-02-25 | Solid support and method of enhancing the recovery of biological material therefrom |
| GB201103258 | 2011-02-25 | ||
| PCT/EP2012/053163 WO2012113906A2 (en) | 2011-02-25 | 2012-02-24 | Solid support and method of enhancing the recovery of biological material therefrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2592963T3 true ES2592963T3 (es) | 2016-12-02 |
Family
ID=43904184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12705857.6T Active ES2592963T3 (es) | 2011-02-25 | 2012-02-24 | Soporte sólido y método para aumentar la recuperación de material biológico del mismo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10876938B2 (enExample) |
| EP (1) | EP2678692B1 (enExample) |
| JP (1) | JP6074369B2 (enExample) |
| CN (1) | CN103460051B (enExample) |
| AU (1) | AU2012219482B2 (enExample) |
| CA (1) | CA2828158C (enExample) |
| ES (1) | ES2592963T3 (enExample) |
| GB (1) | GB201103258D0 (enExample) |
| WO (1) | WO2012113906A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107208136A (zh) | 2014-12-18 | 2017-09-26 | 通用电气医疗集团英国有限公司 | 通过与免疫测定法偶联的核酸扩增的固体支持物上的分析物检测 |
| HK1258397A1 (zh) | 2015-09-09 | 2019-11-08 | Drawbridge Health, Inc. | 用於样品收集、稳定化和保存的系统、方法和装置 |
| SG10201911879UA (en) | 2017-01-10 | 2020-01-30 | Drawbridge Health Inc | Devices, systems, and methods for sample collection |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| JP7772425B2 (ja) * | 2022-03-23 | 2025-11-18 | 株式会社ミルテル | ニコチンアミドアデニンジヌクレオチド（ｎａｄ＋）又はニコチンアミドモノヌクレオチド（ｎｍｎ）を定量する方法、並びにその方法を実施するためのキット及び濾紙 |
| WO2025249073A1 (ja) * | 2024-05-30 | 2025-12-04 | 国立大学法人大阪大学 | 目的化合物を選択的に採取するためのデバイス、該デバイスの製造方法、および生体または環境試料から目的化合物を選択的に採取するための方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US575126A (en) | 1897-01-12 | Watch-pocket guard | ||
| BE542544A (enExample) * | 1954-11-04 | |||
| US3227075A (en) | 1961-04-04 | 1966-01-04 | Fitchburg Paper | Planographic printing plates |
| JPS5319092A (en) | 1976-11-08 | 1978-02-21 | Shionogi Seiyaku Kk | Composite for liver desease detection |
| JPH01291164A (ja) | 1988-05-19 | 1989-11-22 | Fujirebio Inc | 標準瀘紙用組成物 |
| US5985327A (en) | 1988-10-05 | 1999-11-16 | Flinders Technologies Pty. Ltd. | Solid medium and method for DNA storage |
| US5756126A (en) | 1991-05-29 | 1998-05-26 | Flinders Technologies Pty. Ltd. | Dry solid medium for storage and analysis of genetic material |
| US5188938A (en) * | 1988-12-29 | 1993-02-23 | Microgenics Corporation | Enzyme quantitation wicking assay |
| US5756362A (en) | 1993-10-12 | 1998-05-26 | Cornell Research Foundation, Inc. | Liposome-enhanced immunoaggregation assay and test device |
| US6132971A (en) * | 1995-06-27 | 2000-10-17 | The University Of North Carolina At Chapel Hill | Microelectronic device |
| US5804684A (en) * | 1995-08-24 | 1998-09-08 | The Theobald Smith Research Institute, Inc. | Method for isolating nucleic acids |
| JPH10179722A (ja) | 1996-12-25 | 1998-07-07 | Sumitomo Bakelite Co Ltd | 表面処理 |
| US5939259A (en) | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
| EP2290099B1 (en) * | 1998-02-02 | 2012-10-10 | QIAGEN North American Holdings, Inc. | Processes for isolating, amplifying and characterizing DNA |
| US6187540B1 (en) * | 1998-11-09 | 2001-02-13 | Identigene, Inc. | Method of newborn identification and tracking |
| ES2308865T3 (es) | 1999-03-11 | 2008-12-01 | Whatman, Inc. | Medio solido y procedimiento para el almacenamiento y la rapida purificacion de acido nucleico. |
| WO2003020924A2 (en) | 2001-09-05 | 2003-03-13 | Whatman Plc | Stable storage of proteins |
| US20030215358A1 (en) * | 2002-01-15 | 2003-11-20 | Schulman Lloyd S. | Liquid permeable composition in dry reagent devices |
| US7156945B2 (en) * | 2002-04-24 | 2007-01-02 | Sipix Imaging, Inc. | Process for forming a patterned thin film structure for in-mold decoration |
| JP5441290B2 (ja) * | 2002-10-04 | 2014-03-12 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | 核酸精製システムの媒体上に核酸を保存するツールとして、化学物質を用いる方法および材料 |
| US7521021B2 (en) * | 2003-11-26 | 2009-04-21 | Leica Biosvstems St. Louis Llc | System for in situ processing of a tissue specimen |
| US7045295B2 (en) | 2004-04-02 | 2006-05-16 | Hematologics, Inc. | Method for collecting purified cells |
| WO2005102526A1 (en) * | 2004-04-09 | 2005-11-03 | Research Think Tank, Inc. | Devices and methods for collection, storage and transportation of biological specimens |
| US8062901B2 (en) * | 2005-04-30 | 2011-11-22 | Alere Switzerland Gmbh | Devices and methods for sample collection and analysis |
| EP2359943B1 (en) * | 2005-11-08 | 2014-01-22 | SurModics, Inc. | Ultra-thin photo-polymeric coatings and uses thereof |
| WO2008124936A1 (en) * | 2007-04-16 | 2008-10-23 | Mcmaster University | Method of producing bioactive paper |
| CN101892290A (zh) * | 2009-05-19 | 2010-11-24 | 北京协和洛克生物技术研究开发中心 | 苯丙氨酸定量检测试剂盒(酶定量法) |
-
2011
- 2011-02-25 GB GBGB1103258.8A patent/GB201103258D0/en not_active Ceased
-
2012
- 2012-02-24 EP EP12705857.6A patent/EP2678692B1/en active Active
- 2012-02-24 ES ES12705857.6T patent/ES2592963T3/es active Active
- 2012-02-24 JP JP2013554907A patent/JP6074369B2/ja active Active
- 2012-02-24 CN CN201280010442.3A patent/CN103460051B/zh active Active
- 2012-02-24 AU AU2012219482A patent/AU2012219482B2/en active Active
- 2012-02-24 US US13/985,089 patent/US10876938B2/en active Active
- 2012-02-24 CA CA2828158A patent/CA2828158C/en active Active
- 2012-02-24 WO PCT/EP2012/053163 patent/WO2012113906A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2828158C (en) | 2021-10-26 |
| EP2678692B1 (en) | 2016-06-22 |
| EP2678692A2 (en) | 2014-01-01 |
| CN103460051B (zh) | 2015-10-07 |
| GB201103258D0 (en) | 2011-04-13 |
| WO2012113906A3 (en) | 2012-12-20 |
| WO2012113906A2 (en) | 2012-08-30 |
| AU2012219482A1 (en) | 2013-08-29 |
| CN103460051A (zh) | 2013-12-18 |
| JP2014512516A (ja) | 2014-05-22 |
| US10876938B2 (en) | 2020-12-29 |
| JP6074369B2 (ja) | 2017-02-01 |
| US20130330750A1 (en) | 2013-12-12 |
| CA2828158A1 (en) | 2012-08-30 |
| AU2012219482B2 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012219490B2 (en) | Solid support and method of recovering biological material therefrom | |
| AU2012219482B2 (en) | Solid support and method of enhancing the recovery of biological material therefrom | |
| CN108473932A (zh) | 用于样品收集、稳定化和保存的系统、方法和装置 | |
| US20130323778A1 (en) | Paper support and method of recovering biological material therefrom | |
| US11493412B2 (en) | Method and kit for exosomes and associated biomacromolecules capture | |
| US20100221830A1 (en) | Device and Method for Ambient Storage of Fresh/Frozen Tissue Sections Via Desiccation | |
| Kazemi et al. | The role and clinical interest of extracellular vesicles in pregnancy and ovarian cancer | |
| CN102520180B (zh) | 一种胶体金融合乳胶法半定量检测盐酸克伦特罗的检测试剂、试剂条和试剂盒及其制备方法 | |
| Zbikowska et al. | Irradiation dose-dependent oxidative changes in red blood cells for transfusion | |
| JP2017536557A (ja) | 薬物の溶解、吸収及び透過の付随評価のためのシステム、並びに該システムを使用する方法 | |
| St‐Denis‐Bissonnette et al. | Ultracentrifugation and Ultrafiltration Differentially Alter the Composition and Functionality of the Biomolecular Corona of Extracellular Vesicles | |
| US20200400693A1 (en) | Methods for the detection of autologous blood-doping | |
| Skrzypek et al. | Exosomal Protein Markers as Potential Non-Invasive Biomarkers for Colorectal Cancer | |
| EP3695823A1 (en) | Drug storage container, closing member, method for manufacture of drug storage container, method for inspection of microorganisms and contaminants, and solid preparation for buffer solution preparation | |
| Pichurin et al. | Curvature-Encoded Photochemistry for Programmable Isolation and Fractionation of Extracellular and Plasma Membrane Vesicles | |
| Sun et al. | The Formation and Features of Massive Vacuole Induced by Nutrient Deficiency in Human Embryonic Kidney Cells | |
| Liu | Molecular mechanisms of exosome secretion | |
| Meena et al. | Effect of various solute concentrations on the membrane permeability of RBCs in human blood | |
| Cordeiro Freezor | Erythrocytes derived microvesicles: their characterisation and potential role as delivery vectors |